Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study

Urology

Volumn 66, Issue 4, 2005, Pages 726-731

  Bartoletti, Riccardo ^a   Cai, Tommaso ^b   Gacci, Mauro ^b   Giubilei, Gianluca ^b   Viggiani, Fabrizio ^b   Santelli, Giorgio ^b   Repetti, Fabio ^b   Nerozzi, Stefano ^b   Ghezzi, Paolo ^b   Sisani, Michele ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GEMCITABINE;

ABDOMINAL PAIN; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; BCG VACCINATION; BLADDER CARCINOMA; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIURESIS; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DYSPNEA; DYSURIA; FEMALE; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTERSTITIAL CYSTITIS; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; SMELLING DISORDER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URETHRAL PAIN; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 26644473451     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.04.062     Document Type: Article

References (15)

1. D.L. Lamm, P.M. van der Meijden, A. Morales Incidence and treatment of complication of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer J Urol 147 1992 596 600
2. J.B. Thrasher, E.D. Crawford Complications of intravesical chemotherapy Urol Clin North Am 19 1992 529 539
3. J.H. Schiller, D. Harrington, C.P. Belani Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
4. H.A. Burris III, M.J. Moore, J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a randomized trial J Clin Oncol 15 1997 2403 2413
5. S. Miura, Y. Yoshimura, H. Satoh The antitumor mechanism of 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)-cytosine effects of its triphosphate on mammalian DNA polymerases Jpn J Cancer Res 92 2001 562 567
6. L.J. Ostruszka, D.S. Shewach The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine Cancer Chemother Pharmacol 52 2003 325 332
7. M.J. Moore, I.F. Tannock, D.S. Ernst Gemcitabine a promising new agent in the treatment of advanced urothelial cancer J Clin Oncol 15 1997 3441 3445
8. W.M. Stadler, T. Kuzel, B. Roth Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 15 1997 3394 3398
9. V. Lorusso, C.F. Pollera, M. Antimi Italian Co-operative Group on Bladder Cancer A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum Eur J Cancer 34 1998 1208 1212
10. M. Laufer, S. Ramalingam, M.P. Schoenberg Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder a phase I and pharmacokinetic study J Clin Oncol 21 2003 697 703
11. J.A. Witjes, A.G. van der Heijden, J.L.J. Vriesema Intravesical gemcitabine a phase 1 and pharmacokinetic study Eur Urol 45 2004 182 186
12. E. De Beradinis, G. Antonini, G.L. Peters Intravesical administration of gemcitabine in superficial bladder cancer a phase I study with pharmacodynamic evaluation BJU Int 93 2004 491 494
13. G. Dalbagni, P. Russo, J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198
14. W. Oosterlinck, B. Lobel, G. Jakse EAU Working Group on Oncological Urology Guidelines on bladder cancer Eur Urol 41 2002 105 112
15. H.W. Herr, G. Dalbagni Defining bacillus Calmette-Guérin refractory superficial bladder tumors J Urol 169 2003 1706 1708